Action of cannabidiol on the anxiety and other effects produced by ?9-THC in normal subjects

1982/03/01 by A. W. Zuardi, Antônio Waldo Zuardi, Itiro Shirakawa +5 · 609 citations
Chemistry · Medicine · Psychology · Social Sciences · #Antagonism #Anxiety #Anxiolytic #Biology #Cannabidiol #Cannabis #Cannabis and Cannabinoid Research #Chemistry #Diazepam #Diet, Metabolism, and Disease #Internal medicine #Medicine #Pharmacology #Placebo #Psychiatry #Psychology #Volunteer #Youth Substance Use and School Attendance

paper · doi:10.1007/bf00432554

published in Psychopharmacology 76(3), 245-250 (Springer Science+Business Media)

openalex publication_date 1982/03/01 · openalex created_date 2016/06/24 · openalex updated_date 2026/08/05

Citations

• A Cluster Analysis Method for Grouping Means in the Analysis of Variance

Cited by

• Effects of Different Cannabinoid Formulations on Anxiety-Related Disorders, and Tourette Syndrome: A Systematic Review and Meta-Analysis
• Effect of Cannabidiol and Δ9-Tetrahydrocannabinol on Driving Performance
• Does the “Entourage Effect” in Cannabinoids Exist? A Narrative Scoping Review
• Therapeutic potential of cannabidiol (CBD) in anxiety disorders: A systematic review and meta-analysis
• Pharmacokinetics and Metabolism of the Plant Cannabinoids, Δ 9-Tetrahydrocannibinol, Cannabidiol and Cannabinol
• Human Cannabinoid Pharmacokinetics
• The endocannabinoid system as an emerging target of pharmacotherapy. [europepmc]
• Human cannabinoid pharmacokinetics. [europepmc]
• Blunted psychotomimetic and amnestic effects of delta-9-tetrahydrocannabinol in frequent users of cannabis. [europepmc]
• Cannabidiol: a promising drug for neurodegenerative disorders? [europepmc]
• Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. [europepmc]
• Beyond THC: The New Generation of Cannabinoid Designer Drugs. [europepmc]
• Endocannabinoid system and psychiatry: in search of a neurobiological basis for detrimental and potential therapeutic effects. [europepmc]
• Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders. [europepmc]
• Spicing things up: synthetic cannabinoids. [europepmc]
• Does Cannabidiol Protect Against Adverse Psychological Effects of THC? [europepmc]
• Cannabidiol in humans-the quest for therapeutic targets. [europepmc]
• Safety and pharmacokinetics of oral cannabidiol when administered concomitantly with intravenous fentanyl in humans. [europepmc]
• Early Phase in the Development of Cannabidiol as a Treatment for Addiction: Opioid Relapse Takes Initial Center Stage. [europepmc]
• Cannabidiol as a Potential Treatment for Anxiety Disorders. [europepmc]
• The endocannabinoid system as a target for novel anxiolytic drugs. [europepmc]
• A Cross-Sectional Survey of Medical Cannabis Users: Patterns of Use and Perceived Efficacy. [europepmc]
• Patterns of medicinal cannabis use, strain analysis, and substitution effect among patients with migraine, headache, arthritis, and chronic pain in a medicinal cannabis cohort. [europepmc]
• A Cross-Sectional Study of Cannabidiol Users. [europepmc]
• Translational Investigation of the Therapeutic Potential of Cannabidiol (CBD): Toward a New Age. [europepmc]
• Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test. [europepmc]
• The neuropsychopharmacology of cannabis: A review of human imaging studies. [europepmc]
• Potential Adverse Drug Events and Drug-Drug Interactions with Medical and Consumer Cannabidiol (CBD) Use. [europepmc]
• The Effects of Cannabidiol, a Non-Intoxicating Compound of Cannabis, on the Cardiovascular System in Health and Disease. [europepmc]
• Cannabidiol: A Potential New Alternative for the Treatment of Anxiety, Depression, and Psychotic Disorders. [europepmc]
• Effect of Cannabidiol and Δ9-Tetrahydrocannabinol on Driving Performance: A Randomized Clinical Trial. [europepmc]